|Print This Page Email to a Friend|
Carolinas HealthCare System’s Levine Cancer Institute is one of only 150 cancer centers in the nation to offer an innovative treatment for patients with glioblastoma – the most deadly type of brain cancer. The treatment uses a wearable device that delivers electric fields to a patient’s brain via ceramic disks attached to the scalp. The device recently became FDA-approved for its success in reducing the size of brain tumors and prolonging survival in patients with glioblastoma.
“This is a very personalized type of medicine, which could truly be a game-changer for patients who think they have exhausted all other options,” said Ashley Sumrall, MD, neuro-oncologist at the Institute.
Dr. Sumrall, along with Stuart Burri, MD, radiation oncologist, are principal investigator and co-principal investigator on a clinical trial testing these treatments on patients with unresectable glioblastoma, in which chemotherapy and radiation treatment are not sufficient. Levine Cancer Institute is the only site in the nation enrolling patients in the trial, which is only available in Charlotte and at Roper St. Francis in Charleston, SC.
To enroll your patient or learn more about the trial, call Sylvia Rushing at 980-442-2358.
Ashley L. Sumrall, MD
Ashley L. Sumrall, MD, is a neuro-oncologist and medical oncologist at Levine Cancer institute, specializing in primary and secondary brain tumors. With an extensive background in clinical research, Dr. Sumrall has presented original research at multiple national meetings and published widely in peer-reviewed medical literature. In addition to practicing clinical medicine, she authors original clinical trials.
She is a member of the Society of Neuro-Oncology, American Society of Clinical Oncology, and American College of Physician. She is also involved with the North Carolina Oncology Association. She practices in both Charlotte, NC, and Charleston, SC.
Dr. Sumrall has won numerous awards and grants from professional organizations, including the American Medical Association and the American Society of Clinical Oncology. She participates actively in the community, and has volunteered her time with the American Cancer Society, March of Dimes, Junior League of Charlotte, Charlotte Cancer Coalition and medical clinics for the underserved.
Stuart H. Burri, MD
Stuart H. Burri, MD, is the director of Radiation Oncology Research with Levine Cancer Institute. His clinical practice focuses on advanced treatment techniques including high-dose precise radiation for cancer patients. He has consistently been an early adopter of leading-edge technologies, including extra-cranial stereotactic radiosurgery, Glia-site and was the first prescriber in North Carolina of a novel treatment for glioblastoma that uses tumor treating fields (TTFs) to disrupt cell division.
He has actively engaged in clinical research with a special interest in neuro-oncology. He is a member of the American Society for Radiation Oncology, Society of Neuro-Oncology and American Society of Clinical Oncology. He has presented at many national meetings including ASCO, NRG and the Congress of Neurologic Surgeons. His publication highlights include papers in the International Journal of Radiation Oncology Biology Physics, Journal of Clinical Oncology, Neuro-Oncology, Journal of Neuro-Oncology and Journal of the National Medical Association.
Levine Cancer Institute’s World-Class Network and Subspecialty Expertise
Carolinas HealthCare System’s Levine Cancer Institute provides patients with access to nationally renowned physicians and state-of-the-art treatment through a unique delivery model that includes: